|
Calypso Medical Technologies |
|
|
2101 4th Avenue, Suite 1550
Seattle, WA 98121 USA
phone:206-254-0600
fax:206-254-0606
|
|
| Symbol |
Private |
| Founded |
1999 |
| Employees |
|
|
|
| www.calypsomedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| 4D Imaging to Track Prostate Motion and Tumor Location |
|
| Management |
| Eric Meier, President and Chief Executive Officer; J. Nelson Wright, Executive Vice President and Chief Technology Officer; Edward Vertatschitsch, Ph.D., Senior Vice President, Operations; Mark Querry, Vice President, Commercial Operations; James Shock, Vice President, Sales; John Stevens, Vice President, Manufacturing; Marcia Page, Senior Director, Quality Assurance & Regulatory Affairs; Lisa Skrumeda-Levine, Ph.D., Senior Director, Clinical Research |
| |
|
|
| |
|
| Keywords |
| delivery, cancer, target localization, Beacon transponder, radiation, advamed |
|
|
|
| Description |
|
Calypso Medical Technologies, Inc. is a privately-held medical device company focused on improving the accuracy of radiation therapy. The company addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. |
|
| Products / Services |
The company's signature product, the Calypso 4D Localization System (also known as GPS for the Body), can provide objective, accurate and continuous information regarding tumor location. The system also displays and records real-time prostate motion during treatment delivery via its intuitive graphical user interface. Clinicians may then use the data generated by the system to guide radiation therapy setup and to make corrections during treatment delivery if the target falls outside of acceptable boundaries, thereby functioning as a GPS for the Body. In addition, the Calypso 4D Localization System's non-ionizing electromagnetic guidance has been found to improve work flow efficiency and treatment room utilization. The Calypso technology is designed to monitor and treat various cancers undergoing widespread metastasis (i.e. breast and lung). As of July 2006, the FDA granted Calypso 510 (k) clearance to utilize its technologies solely in prostate applications.
|
|
| Technology / Differentiation |
| The technological platform of the Calypso 4D Localization System is based on the detection of electromagnetic markers, or Beacon transponders. The Beacon transponders, each smaller than a grain of rice, are permanently implanted in the prostate before external beam therapy. Once inside the patient, they transmit safe radiofrequency waves to the Calypso system that represent objective location information. The 4D Electromagnetic Array contains the AC electromagnetic source that excites the Beacon transponders and possesses receivers that detect the transponders' positions; it is placed over the patient during external beam therapy. The 4D Array is a component of the 4D Console, which also houses the processor module, power source, and control panel. The Console transfers data to the 4D Tracking Station, which continuously monitors tumor position information in real time and generates daily reports. The final component of the Calypso 4D Localization System is the Optical System, which consists of three infrared cameras determining the position of the 4D Electromagnetic Array. Due to these intricate collaborations among its various technologies, the Calypso 4D Localization System exhibited sub-millimeter electromagnetic localization accuracy without additional non-ionizing radiation (according to phantom measurements under typical conditions of actual use). |
|
| Market / Customers |
About 1.4 million cases of cancer are diagnosed annually in the United States. Over 1.1 million individuals receive some form of radiation therapy for cancer (according to the National Cancer Institute), which provides some insight on how medical radiation equipment evolved into an approximately $2 billion per year industry.
|
|
| Status |
| Calypso announced in May 2008 that its GPS for the Body has been FDA-cleared for use in prostatectomy patients in addition to patients with intact prostates. In January 2009, Calypso announced that Duke University Medical Center was the first in the country to install the latest version of its 4D Localization System, featuring its recently-released Adaptive Workflow Efficiency option, to optimize radiation treatment for its cancer patients. The upgradeable system option includes Adaptive Couch Repositioning, which provides connectivity between the Calypso System and Varian Medical Systems' 4D integrated treatment console (4DITC) to allow an immediate on-line response to organ motion. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members